Fluorescent Probe for Assessment of Renal Elimination

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAaron Cook

About this trial

Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.

Eligibility criteria

Qualifiers

18-65 years old

critically ill or acutely ill hospitalized patients admitted to the intensive care unit

Stable/normal renal function

Disqualifiers

Prisoners

Pregnant women

Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr > 1.5x baseline)

Trial design

Treatments tested in this trial

  • Relmapirazin
  • Iohexol
  • Medibeacon tGFR monitor
  • Urine creatinine clearance collection

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Aaron Cook

Lead sponsor

University of Kentucky

Sponsor institution